Ray Therapeutics to Present at Upcoming Scientific Conferences
We’re delighted to present our data which shows the power of visual optogenetics as a disruptive technology with the potential to restore vision to many patients with retinal blindness.
Ray Therapeutics and Forge Biologics Expand Their Viral Vector cGMP Partnership to Encompass Plasmid DNA Manufacturing
Building on AAV manufacturing partnership with new plasmid production, Forge’s end-to-end manufacturing services will help to advance Ray Therapeutics’ gene therapy for patients living with retinitis pigmentosa and other blinding diseases
Ray Therapeutics Appoints Dr. Peter Francis as Chief Scientific & Medical Officer and Jenny Holt as SVP, Program Portfolio Management
Dr. Francis is a world-renowned clinician scientist and a leader in gene therapy drug development.
Ray Therapeutics Receives $4M in Funding From the California Institute for Regenerative Medicine (CIRM)
The funding will advance development of Ray Therapeutics’ optogenetics technology platform – Company will advance Ray-001 for the treatment of retinitis pigmentosa
Ray Therapeutics and Forge Biologics Announce Viral Vector Contract Development and cGMP Manufacturing Partnership
The manufacturing partnership that will advance Ray Therapeutics’ lead optogenetics gene therapy program, Ray-001, into clinical trials for patients with retinitis pigmentosa.